Last reviewed · How we verify

NCT05193123: RESIREA

Psychological Trauma and Resilience After Critical Illness

Completed Last updated 14 January 2022
What this trial tests

trial in Acute Respiratory Failure in 200 participants. Completed in 16 December 2021.

Timeline
24 October 2018
Primary endpoint
16 March 2021
16 December 2021

Quick facts

Lead sponsorNantes University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date24 October 2018
Primary completion16 March 2021
Estimated completion16 December 2021
Sites23 locations across France

Conditions studied

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Acute Respiratory Failure or Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Critically ill patients experience a severe physical disease, associated with a psychotrauma, which may lead to post-traumatic stress disorder (17 to 30% of patients after critical illness) and persistent symptoms of anxiety and depression. RESIREA study will study psychodrama, resilience and factors associated with resilience in patients previously included in the NUTRIREA-3 randomized controlled trial designed to compare standard calorie and protein feeding complying with guidelines to low-calorie low-protein feeding in a well-defined group of severely ill ICU patients requiring at least MV and vasoactive drugs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Failure

Currently open trials in the same condition.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05193123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing